DaRT Source Radon Release Control for Tumor Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiotherapy methods using ionizing radiation face challenges in delivering targeted doses to tumors while minimizing damage to healthy tissues, particularly due to the limited range of alpha particles, which can be ineffective against hypoxic cells and pose risks to surrounding tissues if not confined properly.
Innovation Solution
The development of diffusing alpha-emitter radiation therapy (DaRT) sources with tailored radon release rates and arrangements, such as hexagonal patterns with specific spacings, to ensure adequate radiation coverage of tumors while minimizing exposure to healthy tissues, using radium-223 or radium-224 atoms that generate chains of radioactive decays with controlled diffusion within the tumor volume.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If alpha particles are used for radiotherapy, then the destructive effect on tumor cells is enhanced, but the short range limits the therapeutic coverage
Solution Approach 1:
The patent segments the alpha-emitting radionuclides into two functional groups: those retained on the source (providing localized high-dose radiation) and those that diffuse away (extending therapeutic range). This segmentation allows simultaneous optimization of both local destructive effect and broader coverage by having different radionuclide populations serve different spatial zones.
Solution Approach 2:
The patent employs a nested structure where daughter radionuclides are generated within the source but can diffuse outward to treat surrounding tissue. The source contains the parent radionuclides (Ra-223 or Ra-224) which decay to produce daughter radionuclides (Rn-219 or Rn-220) that then diffuse away, creating a nested arrangement of radiation sources at different spatial scales.
2Length of moving object
If more radon atoms are released from the source, then the therapeutic range is extended, but healthy tissue may be damaged by cleared daughter atoms
Solution Approach 1:
The patent carefully controls the parameter of radon release rate from the source. By adjusting this release rate parameter, the system optimizes the balance between extending therapeutic range (needing sufficient radon diffusion) and protecting healthy tissue (limiting excess radon clearance). This parameter control allows tuning of the therapeutic window.
Solution Approach 2:
The patent creates different radiation dose distributions at different locations: high concentration of alpha-emitting radionuclides at the source location for maximum local effect, and controlled lower concentration of diffusing daughter radionuclides in surrounding tissue for extended but gentler coverage. This spatial variation in radionuclide concentration implements local quality differentiation.
3Object-affected harmful factors
If conventional radiation is used, then healthy tissue is better protected, but hypoxic cells in tumors are not effectively treated
Solution Approach 1:
The patent uses diffusing daughter radionuclides as intermediaries that can penetrate into hypoxic regions of the tumor where conventional radiation fails. These radionuclides act as mobile carriers of therapeutic effect, reaching cells that are resistant to conventional radiation due to low oxygen levels, while the parent radionuclides remain confined to protect healthy tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise and effective tumor treatment by increasing the therapeutic range of alpha radiation, ensuring sufficient radon release to destroy tumor cells while minimizing exposure to healthy tissues, thus enhancing treatment efficacy and safety.
Implementation Method 1
radium-223 or radium-224 atoms, which generate chains of several radioactive decays
Implementation Method 2
a substantial percentage of their daughter radionuclides (radon-220 in the case of radium-224 and radon-219 in the case of radium-223) leave the source into the tumor, upon radium decay. These radionuclides, and their own radioactive daughter atoms, spread around the source by diffusion
Implementation Method 3
Alpha particles are a powerful means for radiotherapy since they induce clustered double-strand breaks on the DNA, which cells cannot repair
Data Source
AI summary
A method for treating a tumor, comprising identifying a tumor as a squamous cell carcinoma tumor and implanting in the tumor identified as a squamous cell carcinoma tumor at least one diffusing alpha-emitter radiation therapy (DaRT) source (21) with a suitable radon release rate and for a given duration, such that the source (21) provides during the given duration a cumulated activity of released radon between 3.7 Mega becquerel (MBq) hour and 8.6 MBq hour, per centimeter length.